Search the Newsreel

Why Is KPTI Stock Down 69% After-Hours Today?

Karyopharm Therapeutics (KPTI) shares dropped 69% after-hours following the failure of its drug selinexor to meet the primary endpoint in a late-stage trial for endometrial cancer. Despite the setback, the company plans to reduce spending on this program and focus on its myelofibrosis program, …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Be Represent of Investors of Karyopharm Therapeutics Inc. - KPTI

Pomerantz LLP is investigating Karyopharm Therapeutics Inc. (NASDAQ: KPTI) on behalf of investors for potential securities fraud. This investigation follows a significant drop in Karyopharm's stock price after the company disclosed a retention program granting large cash awards to top executives. Investors are encouraged …

Karyopharm Therapeutics Inc (KPTI) Institutional Confidence

Karyopharm Therapeutics Inc (KPTI) has an institutional shareholding score of 5.00, placing it 72nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion increased by 72.34% quarter-over-quarter to 62.56%. James Simons is the largest institutional shareholder, holding 0.47% of outstanding shares.

KPTI|Karyopharm Therapeutics Inc|Price:6.850|Chg%:-0.240

Karyopharm Therapeutics Inc. (KPTI) shows relatively healthy fundamentals and high growth potential, though its valuation is considered fairly valued within the Pharmaceuticals industry. Institutional ownership is high, and analysts have recently rated it as "Buy" with a target price of $14.80. Despite a weak …

BlackRock (NASDAQ: KPTI) reports 5.6% ownership of Therapeutics Inc shares

BlackRock, Inc. has disclosed a 5.6% ownership stake in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) common stock through a Schedule 13G SEC filing. This represents 1,266,084 shares, with BlackRock holding sole voting power over 1,251,563 shares and sole dispositive power over all 1,266,084 shares. The …

Karyopharm Therapeutics Inc (KPTI) Cash Flow

This article from Tradingkey.com provides a detailed cash flow statement for Karyopharm Therapeutics Inc (KPTI), including quarterly and annual data for operating, investing, and financing activities. It presents a comprehensive financial summary, allowing users to evaluate the company's financial health and stability. The data …

Karyopharm Therapeutics Market Sentiment

This article provides an overview of market sentiment for Karyopharm Therapeutics (KPTI), highlighting key signals such as analyst consensus, short interest, options flow, and insider activity. It includes detailed recent analyst actions with target price changes and ratings, as well as news related to …

Commodore Capital LP Acquires New Position in Karyopharm Therapeutics Inc. $KPTI

Karyopharm Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance | TradingKey

This article provides a detailed profile of Karyopharm Therapeutics Inc. (KPTI), a commercial-stage pharmaceutical company focused on cancer treatments. It outlines the company's business scope, financial data, market performance, executive team, and key shareholders, highlighting their lead asset XPOVIO (selinexor).

Karyopharm Therapeutics Inc (KPTI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Karyopharm Therapeutics Inc (KPTI), noting that relevant data regarding business segments and regional revenue have not yet been disclosed by the company. It details the stock's current market performance, including its trading price, daily change, and market …

Karyopharm Therapeutics Inc (KPTI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Karyopharm Therapeutics Inc (KPTI)'s dividend and stock split history. It notes that the company has distributed no dividends over the past five years. However, it lists multiple instances of a 15-to-1 merger stock split scheduled for February 24, …

Karyopharm Therapeutics Inc KPTI Income Statement

This article provides a detailed quarterly and annual income statement for Karyopharm Therapeutics Inc (KPTI), including data from FY2012Q3 through FY2026Q1. It breaks down various financial metrics such as total revenue, cost of revenue, operating expenses, and net income, alongside year-over-year percentage changes. The …

Karyopharm Therapeutics Inc (KPTI) Financial Health: Profitability & Balance Sheet Analysis

Karyopharm Therapeutics Inc (KPTI) has a financial score of 7.80, with a stable financial status and high operating efficiency. The company's latest quarterly revenue increased by 16.83% year-over-year to $35.07 million, and its net profit saw a 4.56% year-over-year increase. The article provides a …

KPTI|Karyopharm Therapeutics Inc|Price:7.410|Chg%:+0.320

Karyopharm Therapeutics Inc. (KPTI) is a commercial-stage pharmaceutical company with relatively healthy fundamentals and high growth potential. Despite a weak stock market performance over the past month, the company shows strong fundamentals and its valuation is considered fairly valued. Analysts have rated KPTI as …

Karyopharm stock trades lower after revenue declines and cash burn widens

Karyopharm Therapeutics Inc. (KPTI) stock is trading lower due to declining product revenue and a widening net loss. The oncology-focused biotech saw a 42.6% year-over-year revenue decrease in fiscal 2023 and an increased net loss of $149.2 million as R&D investments outpaced revenue. The …

KPTI Q2'26 Earnings: revenue estimate is 33.12M USD

Karyopharm Therapeutics Inc. (KPTI) is scheduled to release its Q2'26 earnings on July 30, with an estimated revenue of $33.12 million and an anticipated EPS of -$1.31. Historically, KPTI has shown variability in its revenue and EPS surprise percentages. Investors will be watching these …

Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?

Karyopharm: 'Hold' Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck (KPTI)

Karyopharm Therapeutics (KPTI) Jefferies Global Healthcare Conference 2026 Summary

Karyopharm Therapeutics presented at the Jefferies Global Healthcare Conference 2026, highlighting progress with its lead compound, selinexor (XPOVIO). Key updates included significant improvements in spleen volume reduction and early overall survival signals from the Phase III SENTRY trial in myelofibrosis, and the completion of …

Karyopharm Therapeutics Launches 2026 Leadership Cash Retention Program for Key Executives

Karyopharm Therapeutics Inc. has implemented a 2026 Leadership Cash Retention Program for its key executives, including named executive officers and the CFO, to incentivize their retention during an anticipated period of significant corporate milestones. This program replaces the annual bonus plan for 2026 and …

Karyopharm Therapeutics Slides on Disclosure of Cash-Retention Program for Executives

Karyopharm Therapeutics (KPTI) shares declined by 2.6% after the company disclosed that it would be providing a cash retention program for its executives. The program, designed to incentivize continued employment despite "headwinds" in the biotech sector and to support "key strategic initiatives," will grant …

Karyopharm Therapeutics (NASDAQ: KPTI) grants 2026 cash retention awards to key executives

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) has established a 2026 Leadership Cash Retention Program on July 13, 2026, to ensure the retention of key executives, including its named executive officers and CFO, during a period of anticipated significant catalysts. This program replaces guaranteed amounts from …